Several hematologists will be honored during this year’s ASH Annual Meeting, scheduled for Dec. 9-12 in San Diego.ASH’s honorific awards recognize clinicians and scientists who have made important contributions to the field.
Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.
Immune Thrombocytopenic Purpura (ITP) Symptoms and Treatment healthcentral.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthcentral.com Daily Mail and Mail on Sunday newspapers.